---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42564348.md"
description: "$INSILICO(03696.HK)The recent surge over the past couple of days is due to several factors: Rentosertib entering Phase III clinical trials, with the core drug moving into late-stage validation; a positive profit forecast for mid-2026, indicating the business model is starting to generate revenue and profits; and consecutive collaborations with companies like Lilly, SK, and Takeda, which validate the platform's value among major pharmaceutical firms. After the lock-up pressure, the stock price didn't collapse but was instead absorbed by capital, restoring market confidence.Revaluing from an "AI drug discovery concept stock" to an "AI drug discovery platform biotech." 😃"
datetime: "2026-07-10T03:30:07.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42564348.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42564348.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42564348.md)
author: "[清禾](https://longbridge.com/en/profiles/13068398.md)"
---

# $INSILICO(03696.HK)The recent surge over the past …


### Related Stocks

- [03696.HK](https://longbridge.com/en/quote/03696.HK.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)